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Purpose: Giant intracranial aneurysms commonly cause poor clinical outcome and few
studies focus on them. This study is to retrospectively report the angiographic and clinical
presentations in unruptured giant saccular vertebrobasilar aneurysms with and without
endovascular treatment.
Methods: Out of 400 patients who had unruptured posterior circulation aneurysms in a single
center, we found 10 unruptured giant (>25 mm) saccular vertebrobasilar aneurysms. Clinical
and angiographic presentations as well as their clinical outcomes were assessed.
Results: Of the 10 giant aneurysms in 10 patients, three were left untreated. During 6 months
follow-up, all 3 of these patients died from aneurysm rupture. The remaining 7 patients were
treated by endovascular procedure, 5 received stent-assisted coiling, 1 was treated by parent
artery occlusion (PAO), and 1 was treated by conventional coiling. Of these treated patients,
only one survived during a 22 month period of follow-up.
Conclusions: Patients with giant saccular aneurysms of vertebrobasilar artery presenting
mass effect may have extremely poor clinical outcomes and may not beneﬁt from endo-
vascular treatment.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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The giant intracranial aneurysm is deﬁned as having a
maximum diameter exceeding 2.5 cm and often appears in
saccular form [1–3]. This type of aneurysms accounts for less
5% of all intracranial aneurysms and is rare in the region of
posterior circulation [2,4]. Aneurysms of posterior circulation,
especially vertebrobasilar aneurysms, can lead to extremely* Corresponding author at: Beijing Neurosurgical Institute, Beijing T
Dongcheng District, 100050 Beijing, PR China. Tel.: +86 010 67098852; 
E-mail address: liyouxiang@263.net (Y. Li).
http://dx.doi.org/10.1016/j.pjnns.2016.04.001
0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Spoor clinical presentations or fatal outcome such as ischemic
effects, hydrocephalus, mass effect on the adjacent cranial
nerves and brainstem, and common manifestations of acute
subarachnoid hemorrhage [5–8]. Zhang et al. reported that 4 of
5 untreated patients with giant vertebrobasilar aneurysms had
poor clinical outcomes [9]. Owing to the proximity of the
brainstem and its complex neuroanatomy, the surgical
procedure for giant vertebrobasilar aneurysm commonly
confronts access limitations and technical challenges [7,10].iantan Hospital, Capital Medical University, No. 6, Tiantan Xili,
fax: +86 010 67098852.
p. z o.o. All rights reserved.
Fig. 1 – A vertebrobasilar junction giant saccular aneurysm. A 58-year-old man presented numbness. (A) Axial T1 MR imaging
scan showed a giant mass in front of the pons. (B) Right vertebral artery angiogram showed a giant saccular aneurysm and
the absence of basilar artery. (C) Left vertebral artery angiogram showed that the blood supply of left vertebral artery was not
sufficient. This patient received conservative treatment because of a technical failure during the endovascular procedure. He
died of aneurysmal rupture 6 months later.
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management for giant vertebrobasilar aneurysms was only
28.5% [7]. Additionally, results of a small study (8 patients)
showed that endovascular embolization of giant vertebrobasilar
aneurysms were also relatively difﬁcult to cure [11]. However,
there were few studies investigating highly complex giant
aneurysms. The aim of this study is to report the challenges
surrounding the current endovascular treatment methods of
unruptured giant saccular vertebrobasilar aneurysms.
2. Methods and materials
A total of 10 consecutive patients with 10 unruptured giant
saccular aneurysms of vertebrobasilar artery were enrolled
between January 2008 and December 2014 at our hospital. All
participants have signed the informed consent to participate
in this study before they received endovascular treatment and
the study was approved by the ethics committee of our
hospital. There were 8 males and 2 females, and their meanFig. 2 – A left vertebral artery giant aneurysm. A 77-year-old ma
dysarthria, nystagmus and hypoesthsia. (A) Left vertebral artery
aneurysm located at left vertebral artery, which was treated by 
frontal views: giant aneurysm was embolized incompletely. (C) 
hemorrhage from the rupture of the giant aneurysm. The patienage is 41.4 years (range 29–77 years). These patients had no
history of subarachnoid hemorrhage (SAH). Clinical charac-
teristics, including demographic characteristics, radiological
ﬁndings such as computed tomography angiography (CTA),
magnetic resonance angiography (MRA), digital subtract angi-
ography (DSA) and medical reports were retrospectively
reviewed. All patients underwent cerebral DSA with three-
dimensional (3D) reconstruction to conﬁrm the dome and neck
of aneurysm, the parent artery, and the origin and trajectory of
nearby arterial branches for assisting the plan of treatment.
Representative cases are provided in Figs. 1 and 2.
Nine patients presented with headache or severe neuro-
logic deﬁcits (Tables 1 and 2), one patient was detected
incidentally. Four aneurysms involved the basilar artery, three
aneurysms involved vertebral artery and three aneurysms
were located at vertebrobasilar junction. These 10 aneurysms
were saccular in shape and the size ranged from 25 to 40 mm
(31.0 mm  6.2 mm).
Giant saccular aneurysm commonly has a wide-neck and is
difﬁculty to be occluded. Intracranial stent system couldle presented with severe headache, gait disturbance,
 angiogram (frontal views) showed a giant saccular
stent-coils embolization. (B) Post-operative angiogram in
Emergency post-operative CT scan showed subarachnoid
t lost consciousness rapidly and died 3 days later.
Table 2 – Endovascularly treated patients' demographics, treatment and outcomes.
No. Age Sex Size
(mm)
Location Symptoms Pre-mRS at
admission
Treatment
summary
Occlusion Clinical
outcome
Follow-up
(months)
1 38 M 30  30 VBJ Dysphagia, numbness,
gait disturbance
4 Stent/coil (silk) Complete Died POD1
(hemorrhage)
–
2 44 M 36  26 BA Vertigo, numbness 2 Stent/coil
(Enterprise/
solitaire)
Incomplete Died POD1
(compression)
–
3 29 M 35  30 VBJ Vertigo, vomit, numbness,
dysphagia
3 Stent/balloon
(Enterprise)
PVO Died POD4
(artery occlusion)
–
4 44 M 26  15 LVA Asymptomatic 0 Stent/coil
(Enterprise)
Incomplete Asymptomatic 22
5 31 F 40  35 TOBA Limb asthenia, visual
blurring, gait disturbance
4 Stent/coil
(Enterprise)
Incomplete Died POD5
(compression)
–
6 77 M 25  25 LVA Headache, gait
disturbance, dysarthria,
nystagmus
4 Stent/coil
(Neuroform)
Incomplete Died POD3
(hemorrhage)
–
7 44 M 25  18 TOBA Headache, visual blurring,
vomit
3 Coil Incomplete Died
(compression)
7
LVA, intracranial segment of the left vertebral artery; BA, basilar artery; VBJ, vertebrobasilar junction; TOBA, the top of basilar artery; PVO,
parent vessel occlusion.
Table 1 – Untreated patients demographics and outcomes.
No. Age Sex Location Size (mm) Symptoms Pre-mRS at
admission
Follow up
(month)
Clinical
outcome
1 60 M BA 26  23 Vertigo, gait disturbance 4 1 Died
2 65 F RVA 27  22 Headache, vomit, diplopia 3 2 Died
3 58 M VBJ 40  30 Numbness 2 6 Died
RVA, intracranial segment of the right vertebral artery; BA, basilar artery; VBJ, vertebrobasilar junction.
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scaffold for endothelialization. When a stent was planned,
antiplatelet therapy consisting of clopidogrel 75 mg and aspirin
100 mg was administered for at least ﬁve days before endovas-
cular procedure. During the treatment process, 3000 IU of small
molecule heparin was given at the beginning of each implanta-
tion and 1000 IU administered intravenously thereafter every
hour. After the procedure, the patient was recommended with
75 mg clopidogrel for an additional 30 days, and 100 mg aspirin
for an additional 6 months. One patient was treated by silk ﬂow
diverter and received 300 mg aspirin combined with 75 mg
clopidogrel daily during the time of periprocedure.
The clinical follow-up was supplemented by telephone
interviews for a period ranging from 1 to 22 months.
Angiographic follow-up data was obtained for only 1 survival
patient at 3 months. Besides, this patient received a clinical
visit at 22 months after the endovascular procedure.
3. Results
Three patients encountered a technical failure during the
endovascular procedure (one failed in navigating guiding
catheter into vertebral artery, two failed in delivering the stent
microcatheter across the neck of aneurysms), and they had to
receive conservative treatment. The other seven patients were
treated by endovascular embolization. Of the 7 treated
patients, 6 of them received stent-assisted coils embolization(one Neuroform, one Silk, one Enterprise & Solitaire, three
Enterprise). One aneurysm was occluded with conventional
coils. One aneurysm was treated by parent artery occlusion
(PAO) with a detachable balloon and the deployment of
Enterprise stent in the contralateral vertebral artery. Immedi-
ate post-procedural angiography revealed complete occlusion
in only 1 patient (treated by coils and silk stent) and
incomplete (partial or nearly complete) occlusion in 6 patients
(four treated by coils combining with stents, one treated by
PAO, one treated by conventional coils).
4. Outcome
During the follow-up period, extremely poor clinical outcomes
were found. Three untreated patients (Table 1) died due to an
aneurysmal hemorrhage which was conﬁrmed by CT scanning
at 1 month, 2 months and 6 months. Of the 7 treated patients
(Table 2), endovascular embolization resulted in only 1
excellent outcome and 6 deaths by 7 months after procedure.
Among these 6 dead cases, 3 were caused by severe brainstem
compression after partial occlusion, 2 by fatal hemorrhage and
1 by the failure of collateral blood ﬂow after bilateral vertebral
artery occlusion. Of the two hemorrhage cases: one was
caused by intraoperative bleeding; the other one received silk
stent-assisted coils embolization and died of post-operative
hemorrhage 4 days later. The survival patient was occluded
near-completely by Enterprise stent-assisted coiling.
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Although there have been reports which demonstrated that
giant (≥25 mm) intracranial aneurysms have a dismal natural
progression, with neurological deterioration or fatal outcomes
caused by rupture, ischemic events, or progressive mass effect
[5], more details are needed for the decision of treatment
strategy of unruptured giant saccular aneurysms of vertebro-
basilar artery. The results of this small study of patients with
unruptured giant saccular vertebrobasilar aneurysms showed
3 deaths of untreated cases and 6 deaths among 7 patients
treated by endovascular management.
Choi and David demonstrated that a giant aneurysm may
be the result of progressive, complex changes of a small
aneurysm, due to hemodynamic stress and secondary healing
response [2]. Swearingen and Heros considered that the risk of
rupture increased with the size of aneurysms [12]. The
potential of enlargement and eventually rupture of giant
saccular vertebrobasilar aneurysms should not be neglected.
Vertebrobasilar giant aneurysms could grow rapidly in a short
time causing mass effect of brainstem and eventually rupture
[13]. An international study indicated that unruptured giant
aneurysms located at posterior circulation had a 50% rupture
rate over a 5 year period [14]. Consistent with previous reports
[15] of a 100% mortality rate within 2 years in untreated giant
posterior circulation aneurysms, the 3 untreated patients in
our study died of aneurysmal rupture within 6 months. Our
study shows that unruptured giant saccular aneurysms of the
vertebrobasilar artery have extremely disastrous natural
progression if left untreated.
Treatment strategies are mostly inﬂuenced by the clinical
presentation [16]. Kobayashi et al. concluded that interven-
tional treatment (including endovascular and surgery)
should be required under the condition of developing
symptoms associated with mass effect or signiﬁcant neuro-
logical deﬁcits [17]. Except for the risk of rupture, the initial
clinical symptoms caused by mass effects seem to be an
important factor to estimate the clinical outcomes when
patients receive endovascular treatment. In our study, all of
the 9 patients with signiﬁcant mass effects died. In the series
of treated patients, although endovascular embolization
changed the hemodynamics and induced the formation of
intra-aneurysm thrombus, this technique increased aneu-
rysm hardness substantially and did not release the initial
compression of the brainstem in a short amount time.
Darsaut et al. found that patients with poor baseline
functional status, giant aneurysms, and aneurysms located
at the vertebrobasilar artery predicted dismal outcomes at
the ﬁnal follow-up [5]. Similarly, Iihara et al. reported a study
containing 12 giant vertebrobasilar aneurysms (saccular and
fusiform) with signiﬁcant mass effect treated by endovas-
cular management or surgical management, and found that
only 5 patients had improved outcomes or no complications
[7]. In their report, 4 of 5 remaining patients whose giant
aneurysms of the vertebrobasilar artery were detected
incidentally had good or stable clinical prognosis. There
was only 1 patient without initial clinical symptoms in our
study who received stent-coils embolization obtaining an
excellent prognosis.PAO is a deconstructive therapy [18]. This technology is
commonly planed for patients who have adequate collateral
ﬂow and can tolerate occlusion [9,16]. Vertebral artery
occlusion has been well established [16], however, this
technology is not the optimal treatment for every giant
aneurysm. A report reviewed a case which received endovas-
cular PAO and failed to block blood ﬂow to the vertebral artery
aneurysmal neck due to the vasa vasorum [19]. Long-term
follow-up is still awaited to assess the risk of ischemic
complications and even the appearance of new aneurysms
which were caused by the resultant changes in hemodynamics
[20]. For patients treated by right vertebral artery occlusion
using a combination of a detachable balloon and an Enterprise
stent implantation in the left vertebral artery, the status of the
circulation or compensatory of posterior communicating
arteries and effective antiplatelet therapy should be required
before procedure.
Some novel ﬂow diverters and endoluminal reconstruc-
tion devices (such as pipeline, silk, surpass stent) have been
used for treating complex aneurysm extensively [6,21].
However, like other type of stents, ﬂow diverters have the
risk of sudden in-stent thrombosis and catastrophic bleeding
complications [11,22]. Recently, experiences and results from
ﬂow diverters used in the treatment of aneurysms showed
devastating immediate or delay ipsilateral intraparenchymal
hemorrhage [23]. Alderazi also indicated that antiplatelet
therapy could complicate the use of ﬂow diverters and
faciliate rebleeding of ruptured aneurysms after stent-
assisted treatment [24]. Fox reported a case of early
aneurysmal rupture following treatment using ﬂow diver-
sion [25]. Another study demonstrated the fatal hemorrhagic
complication of the silk stent when used during antiplatelet
therapy [26]. Kulcsár et al. found 3 basilar artery aneurysms
ruptures following the implantation of a silk stent [27].
Meckel et al. [28] reported a study containing of 10 complex
aneurysms at the vertebrobasilar junction treated by ﬂow-
diverting stents and 4 cases died. A literature [29] referring to
the long-term follow-up of the pipeline reminded that giant
vertebrobasilar aneurysms may not be beneﬁted from the
ﬂow-diverter embolization (3 death in 4). There is still
insufﬁcient data to support the efﬁciency of ﬂow-diverters
for unruptured giant saccular aneurysms of vertebrobasilar
artery.
6. Limitations of the study
Our study has limitations. First, there were not sufﬁcient cases
with unruptured giant saccular vertebrobasilar aneurysms in
our institution from 2009 to 2014. Second, few patients
accepted the angiography as the method of follow-up.
7. Conclusion
The rupture of giant vertebrobasilar aneurysms commonly
causes immediately fatal intracranial hemorrhage, even after
receiving endovascular treatment. Unruptured giant saccular
aneurysms of the vertebrobasilar artery with mass effect may
not beneﬁt from this technology completely.
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